Back to Journals » OncoTargets and Therapy » Volume 9

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

Authors Patel S, Gill D, Garrido-Laguna I

Received 7 May 2015

Accepted for publication 27 October 2015

Published 30 December 2015 Volume 2016:9 Pages 75—86


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Liying Geng

Peer reviewer comments 4

Editor who approved publication: Professor Daniele Santini

Shiven B Patel,* David Gill,* Ignacio Garrido-Laguna

Department of Internal Medicine, Oncology Division and Center for Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

*These authors contributed equally to this work

Abstract: Targeted therapies against EGFR, vascular endothelial growth factor, and vascular endothelial growth factor receptor have expanded treatment options for patients with metastatic colorectal cancer (mCRC). Unfortunately, biomarkers to identify patients that are most likely to derive benefit from targeted therapies in this disease are still needed. Indeed, only RAS mutations have been identified as predictive of lack of benefit from monoclonal antibodies against EGFR in patients with mCRC. Panitumumab is a fully humanized monoclonal antibody against EGFR. In this study, we review data to support the use of panitumumab in combination with a chemotherapy backbone, in the first line setting in patients with RAS wild-type mCRC. Ongoing efforts are aimed at identifying smaller subsets of patients within the RAS wild-type group that will derive the largest benefit from anti-EGFR therapy. In the meantime, treatment with anti-EGFR therapy should be reserved for patients with RAS wild-type mCRC.

Keywords: panitumumab, metastatic colorectal cancer, first-line, RAS

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]